4.9/5
( 082+ reviews)
Features J2P-MC-LXBD
A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study to evaluate the efficacy and safety of 3 dose levels of BID administered LY3556050 in Adult Participants with Diabetic Peripheral Neuropathic Pain.
📚
Learning Tools
Enhance your learning experience with interactive features.
🏠
Smart Home
Control and monitor your home with smart features.
🛡️
Secure & Private
Your data is protected with industry-leading security protocols.
Screenshots
See the J2P-MC-LXBD in Action
Get the App Today
Download on Google Play
Available for Android 8.0 and above